Longevity investors investing in anti-aging biotech in 2026

Longevity went from fringe science to serious biotech in three years. Most investors still confuse healthspan extension with wellness apps. The ones on this list actually funded companies through Phase 2 trials and understand the difference between rapamycin analogs and NAD+ supplements.

Quick list

Picking investors who understand longevity science

Experience: Find investors who've backed biotech through clinical trials, not just preclinical hype. Ask their portfolio companies about support during Phase 2 failures. Most longevity startups pivot their lead indication three times before finding something that works.

Network: Check if they can intro you to FDA consultants, geroscience researchers, or pharma corp dev teams. Generic biotech connections won't help when you need someone who understands aging biology endpoints at the FDA.

Alignment: Wellness investors won't understand 10-year drug development timelines. Rapamycin researchers and NAD+ supplement sellers have completely different businesses. Investors who funded supplement companies will push for faster revenue instead of proper clinical validation.

Track record: Look at whether their longevity portfolio companies published peer-reviewed data or just press releases. Companies that never shared actual lifespan data in model organisms are red flags, especially if they couldn’t provide structured investor updates during delays.

Communication: Use Ellty to share your deck with trackable links. You'll see who actually opens your preclinical efficacy data versus just skimming the market size slides about aging populations.

Value-add: Ask what scientific advisors they provide for geroscience and regulatory strategy. "We have a great network" means nothing if they can't help you design aging biomarker endpoints that the FDA will accept.

Getting meetings with longevity investors

Identify potential investors: Research recent deals on Pitchbook or Crunchbase specifically in longevity, aging biology, or senolytics. General biotech funds that only do oncology won't understand healthspan endpoints. Look for investors who've funded at least one company targeting hallmarks of aging. Prioritize investors who've funded companies with real actuators and motors and who understand early startup fundraising cycles.

Craft a compelling pitch: Show your mechanism of action, lifespan data in model organisms, and clinical trial design upfront. Most investors are tired of "extending healthspan" claims without dose-response curves in mice. Your proof of concept in C. elegans or actual monkey data matters more than your TAM slides. Make sure your pitch deck highlights performance metrics clearly.

Share your pitch deck: Upload to Ellty and send trackable links. Monitor which pages investors spend time on - if they skip your preclinical data slides, that's useful information before you waste time explaining your mechanism. Tools designed to protect PPTs also help present sensitive hardware data securely.

Utilize your network: Message founders from Altos Labs, BioAge, or Unity Biotechnology on LinkedIn and ask about investor expectations during clinical holds or trial design changes. Most will be honest about who actually understood the science versus who panicked.

Attend networking events: Longevity Summit, ARDD (Aging Research and Drug Discovery), and Undoing Aging conferences are where deals happen. Skip generic biotech events where nobody understands the difference between lifespan and healthspan.

Engage on online platforms: Connect with partners on LinkedIn after you've been introduced by a portfolio founder or scientific advisor. Cold DMs to longevity investors rarely work - they want published data or strong scientific validation first.

Organize due diligence: Set up an Ellty data room with your animal study data, IND application drafts, and scientific publications before they ask. It speeds up the process when they want their scientific advisors to review your mechanism.

Set up introductory meetings: Lead with your efficacy data in animal models and your FDA strategy. Don't waste 20 minutes on slides about the $600B aging market - they know the demographics and don't believe the market size estimates anyway. Keep the meeting structured with a clear startup context for timelines and risks.

Why longevity matters in 2026

Ozempic proved that aging-related interventions can be massive commercial opportunities. The FDA started accepting aging biomarkers as clinical endpoints. Rapamycin analogs entered Phase 2 trials for healthspan extension, not just cancer or immunosuppression.

Investors who dismissed longevity as pseudoscience in 2020 are now looking at the clinical data. Brian Armstrong put $50M into NewLimit. Sam Altman backed Retro Biosciences with $180M. The money is serious now, but most VCs still can't evaluate senolytic mechanisms versus autophagy enhancers.

22 top longevity investors

1. Longevity Vision Fund

Dedicated longevity fund that backed Altos Labs through their massive raise and understands both the science and the decade-long timelines required for cellular reprogramming.

• Recent Deals: Altos Labs $3B Series A (2024), Cambrian Bio $100M crossover round (2025)
• LinkedIn: Sergey Young
• Sector Focus: Cellular reprogramming, longevity biotech, healthspan extension
• Stage Focus: Series A, Series B, Series C, Growth
• Location: New York, USA
• Website: longevity.vc

2. Khosla Ventures

Backs contrarian science bets and led NewLimit when most investors thought epigenetic reprogramming for aging was too early-stage.

• Recent Deals: NewLimit $105M Series A (2025), Arcadia Science $30M Series A for exploratory biology (2024)
• LinkedIn: Vinod Khosla
• Sector Focus: Epigenetic reprogramming, aging biology, deep tech biotech
• Stage Focus: Seed, Series A, Series B
• Location: Menlo Park, USA
• Website: khoslaventures.com

3. Andreessen Horowitz

Led Loyal's dog aging drug development when other investors couldn't see how veterinary longevity would accelerate human trials and FDA pathways.

• Recent Deals: Loyal $58M Series B (2024), Fauna Bio $4M seed for comparative longevity (2024)
• LinkedIn: Marc Andreessen, Vijay Pande
• Sector Focus: Aging drugs, longevity biotech, computational biology
• Stage Focus: Seed, Series A, Series B
• Location: Menlo Park, USA
• Website: a16z.com

4. Juvenescence

Purpose-built longevity investment firm founded by Jim Mellon that actually understands senescent cell biology and funds companies through clinical trials.

• Recent Deals: Cleara Biotech $45M Series B (2025), LyGenesis $100M Series B for organ regeneration (2024)
• LinkedIn: Jim Mellon, Greg Bailey
• Sector Focus: Senolytic drugs, cellular reprogramming, regenerative medicine
• Stage Focus: Series A, Series B, Series C
• Location: Douglas, Isle of Man
• Website: juvenescence.ltd

5. Apollo Health Ventures

European longevity-focused fund that backed Shift Bioscience's mitochondrial work when most investors couldn't evaluate the science.

• Recent Deals: Shift Bioscience $23M Series A (2024), Nanna Therapeutics $15M Series A for immunometabolism (2025)
• LinkedIn: Jane Brindle
• Sector Focus: Mitochondrial restoration, healthspan, aging biology
• Stage Focus: Seed, Series A, Series B
• Location: London, UK
• Website: apollohealthventures.com

6. Age1

Fund created specifically to invest in longevity companies, led by folks who actually understand the biology and have pharma development experience.

• Recent Deals: BioAge Labs $170M Series C (2025), Tally Health $10M Series A for aging biomarkers (2024)
• LinkedIn: Kristen Fortney
• Sector Focus: Metabolic aging, age-related diseases, longevity biotech
• Stage Focus: Series A, Series B, Series C
• Location: San Francisco, USA
• Website: age1.com

7. Cambrian Bio

Spun out of Founders Fund with a thesis that aging is the biggest opportunity in biotech, and they're backing tissue regeneration before it's consensus.

• Recent Deals: Marble Therapeutics $15M seed (2024), Turn Biotechnologies $65M Series B for mRNA reprogramming (2025)
• LinkedIn: James Fitzgerald
• Sector Focus: Tissue regeneration, cellular reprogramming, aging interventions
• Stage Focus: Seed, Series A, Series B
• Location: San Francisco, USA
• Website: cambrianbio.com

8. Life Biosciences

Longevity platform company that both develops drugs internally and invests in external companies targeting different hallmarks of aging.

• Recent Deals: Selphagy $18M Series A (2025), Spotlight Therapeutics $30M Series A for RNA editing (2024)
• LinkedIn: Mehmood Khan
• Sector Focus: Autophagy enhancement, hallmarks of aging, aging therapeutics
• Stage Focus: Seed, Series A, Series B
• Location: Boston, USA
• Website: lifebiosciences.com

9. Longevity Fund

Early investor in Repair Biotechnologies and other companies targeting specific aging damage, founded by people from the SENS Research Foundation.

• Recent Deals: Repair Biotechnologies $12M Series A (2024), Ichor Life Sciences $8M Series A for biosensors (2025)
• LinkedIn: Laura Deming
• Sector Focus: Thymus regeneration, damage repair, aging intervention
• Stage Focus: Seed, Series A
• Location: San Francisco, USA
• Website: longevity.fund

10. 8VC

Deep tech fund that backed Retro Biosciences with Sam Altman's $180M commitment for their ambitious autophagy and plasma transfer programs.

• Recent Deals: Retro Biosciences $90M investment (2025), Cradle Genomics $22M Series A (2025)
• LinkedIn: Joe Lonsdale
• Sector Focus: Autophagy, plasma therapies, cellular rejuvenation
• Stage Focus: Series A, Series B, Growth
• Location: Austin, USA
• Website: 8vc.com

11. Methuselah Fund

Named after the oldest person in the Bible, backs radical longevity approaches including organ regeneration and backed LyGenesis through their clinical trials.

• Recent Deals: LyGenesis $100M Series B (2024), Oisin Biotechnologies $20M Series A (2025)
• LinkedIn: Dave Gobel
• Sector Focus: Organ regeneration, extreme longevity, aging reversal
• Stage Focus: Seed, Series A, Series B
• Location: Springfield, USA
• Website: mfoundation.org

12. Kizoo Technology Capital

European fund focused on longevity and rejuvenation biotechnologies, led Oisin's senolytic gene therapy round when most investors couldn't evaluate the mechanism.

• Recent Deals: Oisin Biotechnologies $20M Series A (2025), Underdog Pharmaceuticals $8M seed (2024)
• LinkedIn: Michael Greve
• Sector Focus: Senolytic gene therapy, rejuvenation biotech, aging interventions
• Stage Focus: Seed, Series A, Series B
• Location: Stuttgart, Germany
• Website: kizoo.com

13. Jim Mellon's Juvenescence

Built a portfolio of longevity companies including AgeX and understands both the commercial and scientific sides of regenerative biology.

• Recent Deals: AgeX Therapeutics $25M Series C (2024), Juvenescence AI $10M internal funding (2025)
• LinkedIn: Jim Mellon
• Sector Focus: Regenerative biology, cellular therapies, longevity drugs
• Stage Focus: Series A, Series B, Series C
• Location: Douglas, Isle of Man
• Website: juvenescence.ltd

14. Korify Capital

Russian longevity-focused fund that backed Gero's aging biomarker work and understands computational approaches to aging biology.

• Recent Deals: Gero $15M Series A (2025), Deep Longevity $14M Series A for AI aging clocks (2024)
• LinkedIn: Alexander Pichugin
• Sector Focus: Aging biomarkers, computational longevity, geroscience
• Stage Focus: Seed, Series A
• Location: Moscow, Russia
• Website: korify.vc

15. LongeVC

Purpose-built longevity VC that invests exclusively in healthspan extension and aging biology companies, founded by aging researchers.

• Recent Deals: Underdog Pharmaceuticals $8M seed (2024), Repair Biotechnologies growth round participation (2025)
• LinkedIn: Anar Isman
• Sector Focus: GPCR-targeting longevity drugs, aging therapeutics, healthspan
• Stage Focus: Seed, Series A
• Location: Zug, Switzerland
• Website: longevc.com

16. Healthspan Capital

Focuses on companies extending healthy years of life, not just lifespan, and backed Fauna Bio's comparative genomics approach early.

• Recent Deals: Fauna Bio $4M seed (2024), Longevity Biotech $6M seed for aging interventions (2024)
• LinkedIn: Sergey Young
• Sector Focus: Comparative longevity genomics, healthspan extension, aging research
• Stage Focus: Seed, Series A
• Location: New York, USA
• Website: healthspancapital.com

17. Obvious Ventures

Backs world-positive companies including Gordian Biotechnology's tissue-specific aging approach when most investors wanted systemic interventions.

• Recent Deals: Gordian Biotechnology $57M Series B (2025), NotCo $235M Series D (2024)
• LinkedIn: James Joaquin
• Sector Focus: Tissue-specific aging, regenerative medicine, biotech
• Stage Focus: Series A, Series B, Growth
• Location: San Francisco, USA
• Website: obvious.com

18. Foresite Capital

Healthcare-focused fund that led Unity Biotechnology through clinical trials when their senolytic program hit setbacks and most investors would've walked.

• Recent Deals: Unity Biotechnology $55M Series C (2024), Fountain Life $100M Series B for preventive health (2025)
• LinkedIn: Jim Tananbaum
• Sector Focus: Senolytic therapies, aging diseases, healthcare
• Stage Focus: Series B, Series C, Growth
• Location: San Francisco, USA
• Website: foresitecapital.com

19. Felicis Ventures

Early backer of Elevian's GDF11 restoration work when most investors dismissed the results as too good to be true after the initial controversy.

• Recent Deals: Elevian $46M Series B (2025), Shopify $460M secondary (2024)
• LinkedIn: Aydin Senkut
• Sector Focus: GDF11 restoration, aging biology, growth factors
• Stage Focus: Seed, Series A, Series B
• Location: Menlo Park, USA
• Website: felicis.com

20. Section 32

Healthcare investor that backed Rubedo when most funds couldn't understand the difference between killing senescent cells versus modulating their secretome.

• Recent Deals: Rubedo Life Sciences $40M Series A (2024), Alto Neuroscience $80M Series B (2025)
• LinkedIn: Bill Maris
• Sector Focus: Senescent cell modulation, aging therapeutics, biotech
• Stage Focus: Series A, Series B
• Location: Palo Alto, USA
• Website: section32.com

21. Breakthrough Energy Ventures

Bill Gates' climate fund that invests in longevity through the lens of induced tissue regeneration and its potential impact on healthspan.

• Recent Deals: Cradle Genomics $22M Series A (2025), Commonwealth Fusion Systems $84M (2024)
• LinkedIn: Carmichael Roberts
• Sector Focus: Induced tissue regeneration, cellular reprogramming, biotech
• Stage Focus: Series A, Series B, Growth
• Location: Kirkland, USA
• Website: breakthroughenergy.org

22. OS Fund

Bryan Johnson's fund focused on applied science and genomics, backed multiple longevity companies including Oisin's senolytic platform.

• Recent Deals: Oisin Biotechnologies platform development (2024), Lygos $6M for bioengineering (2024)
• LinkedIn: Bryan Johnson
• Sector Focus: Senolytic platforms, applied genomics, aging science
• Stage Focus: Seed, Series A
• Location: Los Angeles, USA
• Website: osfund.co

Track your longevity investor outreach

These 22 investors closed longevity deals from 2024 to 2026. Before you start reaching out, set up proper tracking so you know who's actually reading your preclinical data versus who's just taking meetings.

Upload your deck to Ellty and create a unique link for each investor. You'll see exactly which slides they view and how long they spend on your mechanism of action versus your market opportunity. Most founders are surprised to learn investors skip the aging demographics slides but spend 10+ minutes reviewing lifespan curves from mouse studies.

When investors ask for your animal study data, IND strategy documents, or scientific publications, share an Ellty data room instead of messy email attachments. Your dose-response curves, histology images, and regulatory timelines in one secure place with view analytics.

Common questions

How do I know if an investor actually understands longevity science?

Ask them to explain the difference between senolytics and senomorphics, or between lifespan and healthspan. If they can't, they'll struggle to evaluate your mechanism or help during clinical trial design.

Should I target dedicated longevity funds or general biotech investors?

Depends on your stage and mechanism. Dedicated longevity funds understand aging biology but write smaller checks. Large biotech funds have more capital but often push you toward disease indications instead of aging itself. Early stage, go with longevity specialists.

How many investors should I contact for a longevity biotech round?

Start with 40-50 for Series A. Longevity is still early and most biotech investors don't understand the space. Expect 12-18 month fundraising cycles if you're pre-clinical. Clinical stage can move faster if you have human data.

When should I set up a data room?

Before your first investor meeting. Longevity investors will immediately ask for your animal study data, mechanism details, and publications. Having everything ready in an Ellty data room cuts due diligence time from months to weeks.

Do investors care about aging biomarker data?

Absolutely. Show methylation clock changes, p16 expression, NAD+ levels, or whatever biomarkers are relevant to your mechanism. Investors want to see biological age reversal, not just organ function improvements. If you don't have biomarker data yet, explain your plan to measure it.

What's the biggest mistake longevity founders make with investors?

Talking about the $600B aging market instead of their mechanism and data. Investors know the market is huge - that's not the question. The question is whether your specific intervention actually works and can get through the FDA. Lead with science, not demographics.